Novain (Oxybuprocaine Hydrochloride)

Oxybuprocaine Hydrochloride acts by reversibly blocking voltage‑gated sodium channels in the membranes of peripheral nerve fibers in the cornea and conjunctiva. This inhibition prevents the initiation and propagation of nerve impulses, resulting in loss of sensation in the treated area. The blockade is localized and temporary, allowing normal nerve function to return shortly after the drug is cleared from the ocular surface.

The specific dose and frequency of Novain are determined by the prescribing eye care professional based on the procedure and patient factors. Typically, a single drop is applied to the conjunctival sac, and additional drops may be used if required, following the clinician’s instructions. Patients should not self‑administer or alter the dosing regimen without medical guidance.

Safety data for Oxybuprocaine Hydrochloride in pregnant or lactating women are limited, and the product is not classified in a specific pregnancy category. Consequently, Novain should be used during pregnancy or breastfeeding only if the potential benefit justifies any potential risk to the fetus or infant, and under the direction of a qualified healthcare provider.

To request Novain, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India’s procurement team will contact the buyer to verify institutional or trade credentials, then provide pricing, availability, shipping details (including any temperature control if needed), and assist with the necessary import documentation for international delivery.

Novain (Oxybuprocaine Hydrochloride) is a short‑acting ester‑type local anesthetic, similar in onset to proparacaine but with a slightly longer duration of action. Compared with lidocaine, it provides more rapid corneal anesthesia and less stinging on instillation. Choice of agent depends on the specific procedure, clinician preference, and patient tolerance, as each anesthetic has a distinct pharmacokinetic profile and side‑effect spectrum.

Novain should be stored at controlled room temperature, preferably below 25 °C, in its original sealed container. The product must be protected from light and moisture, and any opened vial should be used within the time frame specified by the manufacturer, typically a few hours, to maintain sterility and potency. Do not freeze the solution, and keep it out of reach of children.

Novain is administered as a sterile ophthalmic drop. The patient or clinician places a single drop onto the conjunctival sac of the eye to be anesthetized, ensuring the eyelids are gently closed for a few seconds to allow even distribution. The onset of anesthesia occurs within seconds, and the effect lasts for a short period, sufficient for diagnostic or minor therapeutic procedures. No systemic administration is required.

Although rare, serious adverse events can include corneal epithelial defects, ulceration, severe allergic reactions such as anaphylaxis, and persistent loss of corneal sensation leading to infection. Systemic toxicity is uncommon but may occur with excessive dosing or accidental ingestion. Patients should be monitored for signs of severe irritation, visual changes, or systemic symptoms, and the drug should be discontinued immediately if serious reactions are observed.

Novain should be avoided in individuals with a known hypersensitivity to Oxybuprocaine, other ester‑type local anesthetics, or any component of the formulation. It is also contraindicated in patients with active corneal infections, severe ocular surface disease, or those who have recently undergone corneal surgery where epithelial healing is critical. Use in infants, young children, or pregnant women should only be considered when the benefit outweighs the risk and under professional supervision.